EUCTR2015-002488-40-NL进行中（未招募）1 期
The LIPMAT study: Liposomal prednisolone to improve hemodialysis fistula maturation - LIPMAT
eiden University Medical Center0 个研究点开始时间: 2015年9月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients who are scheduled for creation of a radiocephalic AVF for maintenance hemodialysis.
- •2.Male or female = 18 years old.
- •3.Patients are able and willing to give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1.Any concurrent illness, disability or clinically significant abnormality that may, as judged by the investigator, affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol.
- •2.Current participation in another interventional clinical trial or subjects who have received an investigational drug within 30 days prior to the baseline visit.
- •3.History of psychosis.
- •4.History of osteonecrosis
- •5.Previous AVF in the ipsilateral arm.
- •6.Current central venous catheter at the ipsilateral side.
- •7.Treatment with oral, rectal or injectable (including intra-articular) glucocorticoids (CS) within 6 weeks prior to baseline visit. Inhaled glucocorticoids are allowed. Topical steroids are allowed, however subjects should not have received more than 100 gram of a mild to moderate topical corticosteroid cream per week, 50 gram of a potent corticosteroid cream per week or 30 gram of a very potent topical corticosteroid cream per week in the 4 weeks prior to the baseline visit.
- •8.Treatment with immunosuppressant drugs. Treatment with NSAIDs.
- •9.Patients who are unlikely to adequately comply with the trial’s procedures (due for instance to medical conditions likely to require an extended interruption or discontinuation, history of substance abuse or noncompliance).
- •10.Women who are lactating, pregnant (positive pregnancy test at baseline) or planning to become pregnant during the course of the study.
- •11.Unwillingness to use reliable and acceptable contraceptive methods throughout the study and till 3 months after last study medication except for female patients who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or at least 1 year postmenopausal.
- •12.Malignant disease, unless cured. Current prostate carcinoma without current or planned cytostatic therapy is allowed.
- •13.Diabetes mellitus, unless on a stable dose of antidiabetic medication or insulin for at least 4 weeks prior to inclusion.
- •14.Signs of active infection, requiring systemic treatment.
- •15.Positive Quantiferon test.
- •16.Subject with positive hepatitis panel (including hepatitis B surface antigen [HBsAg], and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody [anti-HCV]).
- •17.History of anaphylaxis or severe allergic responses, including to radio-contrast agents.
- •18.Planned live-virus vaccinations.
- •19.Planned surgical interventions or planned elective hospital admissions within 6 weeks after AVF surgery. Planned hemodialysis sessions do not count as an exclusion criterion.
- •20.Abnormal hepatic function (ALT/AST or bilirubin > 2 x upper limit of normal) at the time of the screening visit.
- •21.Clinically significant out-of-range values on hematology panel, at discretion of the Principal Investigator.
- •22.Current substance abuse or alcohol abuse.
研究者
相似试验
已完成
2 期
The LIPMAT study: Liposomal prednisolone to improve hemodialysis fistula maturation10047066vaattoegang bij hemodialysearteriovenous shuntVascular access in hemodialysis10038430NL-OMON44992eids Universitair Medisch Centrum80
终止
2 期
The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula MaturationRenal DialysisHemodynamicsVascular RemodelingNeointimaNCT02495662Leiden University Medical Center30
招募中
2 期
A randomized phase II study comparing liposomal irinotecan + fluorouracil + levofolinate to FOLFIRINOX as second-line chemotherapy for pancreatic cancer (NUPAT-09 trial)D021441Pancreatic cancerJPRN-jRCT1041200082Maeda Osamu40
已完成
2 期
Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00241982Radboud University Medical Center22
已完成
3 期
Evaluation of the clinical effect of Methylprednisolone lozenge in oral lichen planusIRCT20220115053724N1Ahvaz University of Medical Sciences40